SLC-391 + pembrolizumab

SLC-391 + pembrolizumab is a combination therapy being investigated for the treatment of advanced or metastatic non-small cell lung cancer (NSCLC). SLC-391 is a selective AXL inhibitor that disrupts cell division, inhibits tumor growth, and causes cancer cells to die. AXL, a member of the TAM family protein tyrosine kinases (Tyro3, AXL and Mer), plays a key role in cell survival, angiogenesis, metastasis and therapeutic resistance. Pembrolizumab (KEYTRUDA) is an anti-PD-1 therapy that works as an immune checkpoint inhibitor. By inhibiting AXL signaling, SLC-391 has the potential to enhance the anti-tumor immune response and sensitize cancer cells to immune checkpoint inhibitors like pembrolizumab.